Pharmaceutical

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor…

4 months ago

Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)

-- Achieved Primary Endpoint with 30mg Dose of RE104 Demonstrating 23.0-Point Reduction from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)…

4 months ago

Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak

Shareholders stand to receive a significant and attractive cash premium, as the purchase price of US$3.01, with a contingent value…

4 months ago

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) --…

4 months ago

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir,…

4 months ago

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial…

4 months ago

Genflow Biosciences PLC Announces Company Update on Dog Trials

Genflow Advances World's First Longevity Gene Therapy Trial in Dogs with No Adverse Effects Reported LONDON, UK / ACCESS Newswire…

4 months ago

President Trump’s Marijuana Fix? DEA’s Program Exposed: Promises Made, Promises Not Kept

"As President Trump weighs marijuana rescheduling in the coming weeks, the DEA's track record reveals years of mismanagement, empty promises,…

4 months ago

Epic UGM 2025 Survival Guide: Insider Tips for Vendors, Storytellers, and Market Watchers

Black Book Research Marks Its 12th Year on the Ground in Verona with Independent, Vendor-Agnostic Insights for Navigating Epic's Provider-First…

4 months ago